Oragenics,
Inc. (NYSE:MKT - OGEN), a leader in the development of novel,
effective antibiotics and oral care probiotics, today announced that Mr.
Al Fosmoe has joined Oragenics as Senior Vice President
Operations/Product Development. The appointment is directly related to
the progress Oragenics has made in the development of a new pipeline of
novel antibiotics from its lantibiotic platform, and marks the expansion
of the team dedicated to accelerating the progress of the lantibiotic
pipeline.
Mr. Fosmoe brings to Oragenics more than 25 years of product
development, regulatory and commercialization experience in the
regulated healthcare products sector, including biologics and drugs. His
background spans operational and regulatory oversight for the
development of live biotherapeutic products (LBP), biotechnology-derived
products, and various oral care products, as well as advancing drug
candidates through US and EU clinical trials.
Mr. Fosmoe commented, “I am excited by the opportunity to bring a new
class of antibiotics to the market in an environment where these
compounds may serve both existing and future unmet medical needs, and
could potentially help stave off infections around the world. Oragenics
has an exciting pipeline and the scientific wherewithal, especially
through our collaboration with Intrexon, to move these new compounds
into the clinic.”
Dr. John N. Bonfiglio, President and CEO of Oragenics, stated, “The
appointment of Al Fosmoe is a milestone in the progression of Oragenics
from a purely research driven company to a development stage company
with a pipeline of new, potentially useful antibiotics. Together with
our collaborators at Intrexon, we have begun the preclinical development
of these compounds which we expect will lead to an IND filing in
mid-2015.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health in
humans and pets. Oragenics, Inc. has established two exclusive worldwide
channel collaborations with Intrexon Corporation Inc., a synthetic
biology company. The collaborations will allow Oragenics access to
Intrexon's proprietary technologies with the idea of accelerating the
development of much needed new antibiotics that will work against
resistant strains of bacteria and new therapeutic probiotics designed to
alleviate symptoms from oral diseases. Oragenics also develops, markets
and sells proprietary OTC probiotics specifically designed to enhance
oral health for humans and pets, under the brand names Evora
and ProBiora
in more than 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect management’s current views with respect to
future events and performance. These forward-looking statements
are based on management’s beliefs and assumptions and information
currently available. The words “believe,” “expect,” “anticipate,”
“intend,” “estimate,” “project” and similar expressions that do not
relate solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking statements
because they are subject to a variety of risks, uncertainties, and other
factors that could cause actual results to differ materially from those
expressed in any such forward-looking statements. These factors include,
but are not limited to those described in the filings of Intrexon and
Oragenics with the U.S. Securities and Exchange Commission. Any
responsibility to update forward-looking statements is expressly
disclaimed.
Copyright Business Wire 2014